Mignogna Chiara, Signorelli Francesco, Vismara Marco Flavio Michele, Zeppa Pio, Camastra Caterina, Barni Tullio, Donato Giuseppe, Di Vito Anna
Department of Health Science, University "Magna Græcia", Catanzaro, Italy.
Department of Experimental and Clinical Medicine, University "Magna Græcia", Catanzaro, Italy; Hospices Civils de Lyon, hôpital Neurologique et Neurochirurgical "P. Wertheimer", Lyon-Bron, France.
Pathol Res Pract. 2016 Jun;212(6):491-9. doi: 10.1016/j.prp.2016.02.020. Epub 2016 Feb 24.
The survival rate in glioblastoma multiforme patients has scarcely improved in the last decades; however, many new therapeutic strategies have been theorized or developed for these neoplasias. Recently, the inverse correlation observed between patient prognosis and tumor-associated macrophages (TAMs) density in solid tumors has encouraged the development of anti-tumor strategies aiming to target TAMs. As expected, TAMs polarization is influenced by both macrophage localization and tumor microenvironment signals, resulting in a more complex scenario than the simple M1/M2 activation status. Macrophage polarization in glioblastoma has not yet been fully elucidated, and most results have been obtained in experimental non-human settings, with some apparent contradiction. The authors performed a histopathological and immunohistochemical study of 37 cases of glioblastoma in order to characterize the M1 and M2 macrophage populations within TAMs. A high prevalence of CD163+ M2-polarized macrophages was detected in this cohort, whereas iNOS+ macrophages were rarely found. The down-regulation of CD68 expression in microglia/macrophage infiltrating glioblastomas is also reported for the first time. Such a finding is associated with a specific location of TAMs within the lesion, as confirmed by the fact that CD68 staining was lower than CD163, mainly in perivascular areas. The authors discuss the recent literature about the global scenario of macrophage plasticity and polarization in glioblastoma, and suggest some pivotal points for therapeutic applications.
在过去几十年中,多形性胶质母细胞瘤患者的生存率几乎没有提高;然而,针对这些肿瘤已经提出了许多新的治疗策略或进行了开发。最近,在实体瘤中观察到的患者预后与肿瘤相关巨噬细胞(TAM)密度之间的负相关关系,促使了旨在靶向TAM的抗肿瘤策略的发展。正如预期的那样,TAM的极化受巨噬细胞定位和肿瘤微环境信号的影响,导致情况比简单的M1/M2激活状态更为复杂。胶质母细胞瘤中巨噬细胞的极化尚未完全阐明,并且大多数结果是在非人类实验环境中获得的,存在一些明显的矛盾。作者对37例胶质母细胞瘤进行了组织病理学和免疫组织化学研究,以表征TAM中的M1和M2巨噬细胞群体。在该队列中检测到CD163+ M2极化巨噬细胞的高患病率,而iNOS+巨噬细胞很少见。首次报道了小胶质细胞/巨噬细胞浸润胶质母细胞瘤中CD68表达的下调。这一发现与TAM在病变内的特定位置有关,CD68染色低于CD163这一事实证实了这一点,主要是在血管周围区域。作者讨论了关于胶质母细胞瘤中巨噬细胞可塑性和极化的整体情况的最新文献,并提出了一些治疗应用的关键点。